君實生物(688180.SH)業績快報:2020年度營收同比增長105.77% 已擁有30項在研藥物
格隆匯 2 月 26日丨君實生物(688180.SH)披露2020年度業績快報,實現營業收入15.95億元,同比增長105.77%,主要系特瑞普利單抗注射液銷售收入的增長,以及新增技術許可收入所致。
2020年度,公司不斷加強核心產品特瑞普利單抗注射液(商品名:拓益®)的市場推廣力度,快速提升產品的醫院覆蓋率,特瑞普利單抗注射液的銷售收入顯著增長。此外,隨着公司研發成果轉換能力的逐步顯現,公司於報吿期內新增技術許可收入。
報吿期內,公司持續加大研發投入,通過自主研發以及合作開發/權益引入(License-in)等形式不斷豐富和拓展在研產品管線,快速推進現已進入臨牀階段的項目進度並積極儲備和推動臨牀前項目的開發。截至公吿披露日,公司產品管線已擁有30項在研藥物,包括28個創新藥物和2個生物類似藥,覆蓋包括惡性腫瘤、自身免疫系統疾病、慢性代謝類疾病、神經系統類疾病以及感染類疾病在內的五大治療領域。隨着產品管線的不斷豐富和對藥物聯合治療的進一步探索,公司的創新研發領域已經從單抗擴展至包括小分子藥物、抗體藥物偶聯物(ADC)、雙功能融合蛋白、細胞治療等更多類型的藥物開發以及癌症、自身免疫性疾病等下一代創新療法探索。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.